Rinvoq Trial Shows 23% Complete Hair Regrowth in Severe Alopecia

Key points

• The UP-AA program enrolled 1,399 participants across 248 sites in North America, Europe, and China, focusing on those with severe alopecia areata (losing at least 50% of scalp hair).
• At the 30 mg dose, 55% of patients reached the primary endpoint of 80% scalp coverage, compared to 45% at the 15 mg dose and less than 4% on placebo.
• Between 13% and 23% of patients achieved complete scalp regrowth (SALT score of zero), a result not previously seen in Phase 3 trials for this condition.
• The European Commission approved upadacitinib for this indication in July 2026, while AbbVie submitted a supplemental New Drug Application to the FDA in April 2026, with a decision expected in early 2027.
• Safety data showed no major cardiovascular events, malignancies, or deaths during the trial, though common side effects included upper respiratory infections and acne.

Background

Alopecia areata affects approximately 2% of the global population, with 7 million cases in the US. Previous treatments for severe cases were limited and often inconsistent. Our archive notes that earlier coverage in August 2026 highlighted the same trial results, emphasizing the drug's off-label status in the US and the potential for eyebrow and eyelash regrowth. This development follows a broader trend in dermatology of repurposing immune-mediated drugs for hair loss, distinct from recent concerns about hair loss linked to GLP-1 weight-loss drugs.

How outlets are covering it

Intelligent Living provides the most detailed clinical breakdown, highlighting the 23% complete regrowth rate and comparing upadacitinib’s efficacy to other JAK inhibitors like baricitinib and ritlecitinib. PhillyVoice contextualizes the medical data with the human impact, citing actress Jada Pinkett Smith and the psychological toll of the condition, while noting that the American Hair Loss Association views the results as 'very encouraging' despite risks. ThePrint focuses on the headline efficacy of 80% coverage but offers less detail on the regulatory timeline or safety profile compared to the other sources. All outlets agree on the core trial data but differ in emphasis: Intelligent Living focuses on the scientific milestone, PhillyVoice on the patient experience, and ThePrint on the general news value.

Why it matters

This is the first JAK inhibitor to achieve complete scalp regrowth as a ranked secondary endpoint in a Phase 3 trial, offering a new systemic treatment option for a condition that previously lacked effective therapies. For the millions affected, particularly those with severe cases resistant to corticosteroids, this represents a potential shift in standard care, provided the FDA approves the drug in the US. The results also validate the hypothesis that blocking JAK1 signaling can reverse autoimmune hair loss, potentially opening doors for other repurposed therapies.

What to watch

The FDA is expected to make a decision on AbbVie’s supplemental New Drug Application in early 2027. In the interim, US physicians may prescribe upadacitinib off-label, though insurance coverage varies. Longer-term safety data from the 52-week extension period will be crucial for assessing durability and risk profiles, particularly regarding cardiovascular events and infections. Patients should consult dermatologists to weigh the benefits against the boxed warnings associated with JAK inhibitors.